The share repurchase programme runs as from 5 February 2026 and up to and including 29 January 2027 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 3 billion, cf. Corporate Announcement No. 11/2026 of 5 February 2026. The share repurchase programme is initiated and structured in compliance with the Market Abuse Regulation (Regulation (EU) No 596/2014) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”). The following transactions have been made under the program:  Number of shares Average purchase price (DKK) Transaction value (DKK)Accumulated, previous announcement 383,346 932.90 357,623,64816 March 2026 16,448 876.13 14,410,51917 March 2026 16,637 884.52 14,715,74318 March 2026 16,892 872.06 14,730,91519...

EINDHOVEN, the Netherlands, March 23, 2026 (GLOBE NEWSWIRE) — ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury and other movement disabilities, today announces that it will report Full-Year 2025 Financial Results and host a webcast to provide a comprehensive business update on March 31, 2026. Presented by CEO Dave Marver, the webcast will be held at 2:00 p.m. CEST / 08:00 a.m. ET. To join the session, please register using this link. About ONWARD Medical ONWARD Medical is the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities. Building on decades of scientific discovery,...

STMicroelectronics China-manufactured STM32 microcontrollers begin volume productionFirst deliveries of fully made-in-China STM32 microcontrollers to China-based customers are ongoing Localization of STM32 MCU manufacturing starts with high-performance STM32H7 series and will continue with performance-oriented, secure STM32H5 series and new entry-level STM32C5 seriesMarch 23, 2026, China​ – STMicroelectronics (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications, announces the start of general-purpose STM32 microcontroller deliveries manufactured in China. The first batch of STM32 wafers fully produced in China by Huahong for ST is now being delivered to customers in China. This milestone is a major step forward in ST global supply chain strategy, with additional STM32 families,...

Pursuant to Article 241-2 of the General Regulations of the French Financial Markets Authority (Autorité des marchés financiers – the “AMF”), this description details the objectives and terms of the share buyback program of OVH Groupe, which the Board of Directors has decided to implement on the basis of the 17th resolution of the General Shareholders’ Meeting of February 12, 2026. The share buyback program described in this document relates to OVH Groupe shares admitted to trading on the Euronext Paris regulated market under ISIN code FR0014005HJ9 (Ticker: OVH). In accordance with the provisions of Article 241-2 II of the AMF’s General Regulations, during the implementation of the buyback program, any modification to any of the information set out in this description must be disclosed to the public as soon as possible in accordance...

New Rhapsido® REMIX-1 & -2 pooled analysis on symptom control as early as week 1 in chronic spontaneous urticaria (CSU) to be presentedLong-term Cosentyx® data build on extensive body of evidence supporting continuous use in hidradenitis suppurativa (HS) and psoriasisAdditional Cosentyx data in HS include indirect comparison of efficacy and safety vs bimekizumab Basel, March 23, 2026 – Novartis will present data from more than 20 abstracts from its growing immunology portfolio at this year’s American Academy of Dermatology (AAD) Annual Meeting. Presentations include new Rhapsido® (remibrutinib) data highlighting changes in daily itch and hives severity scores at week 1 in patients with chronic spontaneous urticaria (CSU), an indirect comparison on Cosentyx® (secukinumab) safety and flare prevention for patients with hidradenitis...

Allschwil, Switzerland, March 23, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today the dosing of the first healthy volunteer in the first-in-human phase 1 study of BAL2420, evaluating the safety, tolerability and pharmacokinetics of this lipopolysaccharide transport protein A (LptA) inhibitor. BAL2420 belongs to a novel class of antibiotics. It targets LptA, which is part of the lipopolysaccharide transport bridge, an essential structure in Gram-negative bacteria. LptA inhibitors have shown potent and rapid bactericidal activity in vitro and in vivo against Gram-negative bacteria of the Enterobacteriaceae family, such as E. coli and K. pneumoniae, including strains resistant to beta-lactams...

THIS NEWS RELEASE IS NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OF AMERICA TO UNITED STATES NEWSWIRE SERVICES OR UNITED STATES PERSONS CALGARY, Alberta, March 23, 2026 (GLOBE NEWSWIRE) — Questerre Energy Corporation (“Questerre” or the “Company”) reported today on recent public comments by political leaders and observers in Quebec regarding the province’s energy security and the potential role of local natural gas development as well as a notice from the Government. Following the completion of the corporate reorganization in January 2026, the economic rights to the Quebec assets are held by the Series 2 Preferred shareholders of the Company. Michael Binnion, President and Chief Executive Officer of Questerre, commented, “We welcome recent comments and public debate regarding Quebec’s strategic autonomy in energy,...

HONG KONG, March 23, 2026 (GLOBE NEWSWIRE) — Willis, a WTW business (NASDAQ: WTW), today announced it has partnered with Circle Asia to launch a new art insurance facility designed specifically for individual collectors and art galleries in Asia. The facility is the first of its kind in Asia, combining specialist arts insurance expertise from Willis and Circle’s digital platform to deliver a seamless and cost-effective way to insure fine art, jewellery and specie collections. Fine art insurance has traditionally required minimum value thresholds or minimum premium commitments from clients. This new facility offers a significantly lower entry premium, giving collectors and galleries easier access to comprehensive coverage through a single, streamlined solution that meets the evolving needs of Asia’s growing art market. Key benefits...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 23, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has initiated a registrational Phase III clinical trial of HMPL-760 in combination with R-GemOx (rituximab, gemcitabine and oxaliplatin) in patients with relapsed/refractory diffuse large B-cell lymphoma (“DLBCL”) in China. The first patient received the first dose on March 20, 2026. DLBCL is the most common form of aggressive non-Hodgkin lymphoma (“NHL”) worldwide, accounting for approximately 40% of all NHL cases in China.1  In 2022, approximately 81,000 new cases of NHL are estimated to have been diagnosed in China.2 Bruton’s tyrosine kinase (“BTK”) is considered a validated target for drugs that aim to treat certain hematological cancers. HMPL-760 is a highly...

Webcast to be held Monday, March 23rd at 8:00 a.m. ET SAN FRANCISCO and BOSTON, March 22, 2026 (GLOBE NEWSWIRE) — Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced it will report Part A 52-week data from the Phase 2 APEX trial of zumilokibart on Monday, March 23, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Webcast DetailsApogee Therapeutics’ live webcast of the Phase 2 APEX Part A results will begin on Monday, March 23rd at 8:00 a.m. ET. The live webcast can be accessed via this link or the Investors section on the Company’s website at https://investors.apogeetherapeutics.com/news-events/events....